Auxilium Pharmaceuticals

Morgan Stanley has published a report on Auxilium Pharmaceuticals (NASDAQ: AUXL) lowering the price target from $26.00 to $18.00. In the report, Morgan Stanley wrote, " We originally saw an inflection for Xiaflex with broader physician acceptance. The June injection metrics continue to show...

Bank of America has published a report on Auxilium Pharmaceuticals (NASDAQ: AUXL) reviewing the results of a survey the bank had commissioned. In the report, Bank of America wrote, "We commissioned a survey of 75 docs that treat hypogonadism (low testosterone) to help assess the outlook for AUXL's...

Jefferies & Company has lowered the price target on Auxilium Pharmaceuticals (NASDAQ: AUXL) from $39 to $38 and maintains its Buy rating.

Bank of America is maintaining is Buy rating on shares of Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL). “We lowered our sales estimates for Testim based on recent IMS trends and Xiaflex based on a more conservative ramp,” Bank of America writes. “Based on the changes, we lowered 2011E revenue to $...

In a report released today, Deutsche Bank commented on Auxilium Pharmaceuticals (NASDAQ: AUXL). In the report, Deutsche Bank was bullish on the company. Deutsche Bank writes, “Our Buy investment rating on Auxilium is predicated on the significant commercial opportunity for Xiaflex, coupled with a...

Global Hunter is out with its report today on Auxilium Pharmaceuticals (NASDAQ: AUXL), reiterating Buy. In a note to clients, Global Hunter writes, "Upcoming events for Auxilium include Q1 earnings and a three-year safety update in patients with Dupuytren's contracture expected in June. In...

Jefferies & Company has raised the price target on Auxilium Pharmaceuticals (NASDAQ: AUXL) from $36 to $39 and maintains its Buy rating.

In a report published by Oppenheimer, Auxilium Pharmaceuticals (NASDAQ: AUXL) announced an outlicensing partnership with Asahi Kasei Pharma to develop and commercialize XIAFLEX in Japan for Dupuytren's contracture and Peyronie's disease. Oppenheimer said that AUXL will receive a $15M up-front...

Jefferies is maintaining its $36 PT on shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL). “Xiaflex continues to be the main stock driver for AUXL,” Jefferies writes. “We believe Xiaflex adoption is gated by reimbursement concerns rather than clinical concerns, and we anticipate steady Xiaflex...

Deutsche Bank is tweaking its Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) 2011 revenue estimate from $268M to $269M but lowering its 2011 EPS estimate from $(0.56) to $(0.83), primarily on higher R&D and lower gross margins. “We are also modestly lowering our 2012-14 revenue and EPS estimates...

Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) a Buy, with a price target of $44. The analysts said that like many biotech companies, Auxilium Pharmaceuticals, Inc is set to benefit greatly from health care...